Mesothelin: An Immunotherapeutic Target beyond Solid Tumors
Modern targeted cancer therapies rely on the overexpression of tumor associated antigens with very little to no expression in normal cell types. Mesothelin is a glycosylphosphatidylinositol-anchored cell surface protein that has been identified in many different tumor types, including lung adenocarc...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-03-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/6/1550 |
| _version_ | 1797446913541275648 |
|---|---|
| author | Joshua R. Faust Darcy Hamill Edward Anders Kolb Anilkumar Gopalakrishnapillai Sonali P. Barwe |
| author_facet | Joshua R. Faust Darcy Hamill Edward Anders Kolb Anilkumar Gopalakrishnapillai Sonali P. Barwe |
| author_sort | Joshua R. Faust |
| collection | DOAJ |
| description | Modern targeted cancer therapies rely on the overexpression of tumor associated antigens with very little to no expression in normal cell types. Mesothelin is a glycosylphosphatidylinositol-anchored cell surface protein that has been identified in many different tumor types, including lung adenocarcinomas, ovarian carcinomas, and most recently in hematological malignancies, including acute myeloid leukemia (AML). Although the function of mesothelin is widely unknown, interactions with MUC16/CA125 indicate that mesothelin plays a role in the regulation of proliferation, growth, and adhesion signaling. Most research on mesothelin currently focuses on utilizing mesothelin to design targeted cancer therapies such as monoclonal antibodies, antibody–drug conjugates, chimeric antigen receptor T and NK cells, bispecific T cell engaging molecules, and targeted alpha therapies, amongst others. Both in vitro and in vivo studies using different immunotherapeutic modalities in mesothelin-positive AML models highlight the potential impact of this approach as a unique opportunity to treat hard-to-cure AML. |
| first_indexed | 2024-03-09T13:47:25Z |
| format | Article |
| id | doaj.art-ae42b10a32514a7aa95d2b607c4e8f6a |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T13:47:25Z |
| publishDate | 2022-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-ae42b10a32514a7aa95d2b607c4e8f6a2023-11-30T20:56:59ZengMDPI AGCancers2072-66942022-03-01146155010.3390/cancers14061550Mesothelin: An Immunotherapeutic Target beyond Solid TumorsJoshua R. Faust0Darcy Hamill1Edward Anders Kolb2Anilkumar Gopalakrishnapillai3Sonali P. Barwe4Nemours Centers for Childhood Cancer Research & Cancer and Blood Disorders, Nemours Children’s Hospital, Wilmington, DE 19803, USANemours Centers for Childhood Cancer Research & Cancer and Blood Disorders, Nemours Children’s Hospital, Wilmington, DE 19803, USANemours Centers for Childhood Cancer Research & Cancer and Blood Disorders, Nemours Children’s Hospital, Wilmington, DE 19803, USANemours Centers for Childhood Cancer Research & Cancer and Blood Disorders, Nemours Children’s Hospital, Wilmington, DE 19803, USANemours Centers for Childhood Cancer Research & Cancer and Blood Disorders, Nemours Children’s Hospital, Wilmington, DE 19803, USAModern targeted cancer therapies rely on the overexpression of tumor associated antigens with very little to no expression in normal cell types. Mesothelin is a glycosylphosphatidylinositol-anchored cell surface protein that has been identified in many different tumor types, including lung adenocarcinomas, ovarian carcinomas, and most recently in hematological malignancies, including acute myeloid leukemia (AML). Although the function of mesothelin is widely unknown, interactions with MUC16/CA125 indicate that mesothelin plays a role in the regulation of proliferation, growth, and adhesion signaling. Most research on mesothelin currently focuses on utilizing mesothelin to design targeted cancer therapies such as monoclonal antibodies, antibody–drug conjugates, chimeric antigen receptor T and NK cells, bispecific T cell engaging molecules, and targeted alpha therapies, amongst others. Both in vitro and in vivo studies using different immunotherapeutic modalities in mesothelin-positive AML models highlight the potential impact of this approach as a unique opportunity to treat hard-to-cure AML.https://www.mdpi.com/2072-6694/14/6/1550mesothelinacute myeloid leukemiaimmunotherapy |
| spellingShingle | Joshua R. Faust Darcy Hamill Edward Anders Kolb Anilkumar Gopalakrishnapillai Sonali P. Barwe Mesothelin: An Immunotherapeutic Target beyond Solid Tumors Cancers mesothelin acute myeloid leukemia immunotherapy |
| title | Mesothelin: An Immunotherapeutic Target beyond Solid Tumors |
| title_full | Mesothelin: An Immunotherapeutic Target beyond Solid Tumors |
| title_fullStr | Mesothelin: An Immunotherapeutic Target beyond Solid Tumors |
| title_full_unstemmed | Mesothelin: An Immunotherapeutic Target beyond Solid Tumors |
| title_short | Mesothelin: An Immunotherapeutic Target beyond Solid Tumors |
| title_sort | mesothelin an immunotherapeutic target beyond solid tumors |
| topic | mesothelin acute myeloid leukemia immunotherapy |
| url | https://www.mdpi.com/2072-6694/14/6/1550 |
| work_keys_str_mv | AT joshuarfaust mesothelinanimmunotherapeutictargetbeyondsolidtumors AT darcyhamill mesothelinanimmunotherapeutictargetbeyondsolidtumors AT edwardanderskolb mesothelinanimmunotherapeutictargetbeyondsolidtumors AT anilkumargopalakrishnapillai mesothelinanimmunotherapeutictargetbeyondsolidtumors AT sonalipbarwe mesothelinanimmunotherapeutictargetbeyondsolidtumors |